TY  - JOUR
T1  - LOw-molecular-weight heparin as an adjunct to thrombolysis in st elevation myocardial infarction
AU  - Quinlan DJ, Eikelboom JW
Y1  - 2009/06/22
N1  - 10.1001/archinternmed.2009.126
JO  - Archives of Internal Medicine
SP  - 1163
EP  - 1164
VL  - 169
IS  - 12
N2  - 
The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)–Thrombolysis in Myocardial Infarction (TIMI)-25 study1 demonstrated that the administration of enoxaparin sodium, 30 mg intravenously, followed by subcutaneous injections of 1 mg/kg twice daily (dose modified in patients 75 years or older), compared with intravenous unfractionated heparin (UFH), 60 U/kg bolus (maximum 4000 U), followed by 12 U/kg/h (initial maximum, 1000 U/h, and subsequently adjusted to maintain an activated partial thromboplastin time of 1.5-2.0 times the control value), reduced the risk of nonfatal reinfarction in patients with ST elevation myocardial infarction (STEMI) treated with thrombolysis. Because the ExTRACT-TIMI 25 study seems likely to be the last large trial evaluating the efficacy and safety of low-molecular-weight heparin (LMWH) in patients with STEMI, we added the results of this pivotal 20 000 patient trial to our meta-analysis published in 2005.2 Our updated literature search identified 1 additional study by Wang and colleagues3 published in 2006 involving 186 patients with STEMI who were randomized to receive parnaparin sodium or UFH; this study was also added to our meta-analysis.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2009.126
UR  - http://dx.doi.org/10.1001/archinternmed.2009.126
ER  -